Clinical trials rarely go exactly as planned—dose changes, re‑blinding, and protocol amendments are inevitable. Yet many delays aren’t caused by science, but by fragmented outsourcing models. This webinar, industry experts explore how integrating clinical manufacturing with primary & secondary packaging helps sponsors reduce risk, eliminate the hidden “coordination tax,” and protect critical timelines. Attendees will gain practical insights into building a flexible clinical supply strategy while minimizing risks with an “under one roof” approach.
What are the benefits of Using a CMO for Clinical Manufacturing, Primary & Secondary Packaging?
- Speed, Flexibility & Protection of the Clinical Timeline
A qualified CMO allows sponsors to move faster by absorbing operational complexity and enabling rapid response to change. When manufacturing and packaging sit within or alongside the same quality‑controlled network, mid‑study adjustments (dose changes, re‑blinding, count changes) can be executed without introducing new vendors or delays.
Key advantages include:
- Reduced handoffs between vendors
- Faster response to protocol amendments
- Packaging does not become the critical path
- Single Quality System = Lower Compliance Risk
Using a CMO with integrated manufacturing and packaging operations significantly reduces regulatory and documentation risk. A single Quality Management System (QMS):
- Eliminates re‑qualification when work transfers between parties
- Reduces documentation drift
- Simplifies deviation management and CAPA oversight
For global trials, CMOs operating under FDA, EMA, and Annex 13/16 expectations provide regulatory continuity across regions, which sponsors consistently value during inspections and audits.
- Access to Specialized Expertise and Infrastructure
CMOs bring pre‑validated infrastructure and scarce technical expertise that would be impractical for most sponsors to build in‑house—particularly in early and mid‑phase development. This includes:
- Blinding, over‑encapsulation, re‑packaging
- Controlled environments (humidity, nitrogen purge, cold chain)
- Specialist formats (bottles, blisters, sachets, PFS, gene therapy handling)
Post‑pandemic workforce constraints further increase the value of CMOs with embedded, on‑site experts who can make real‑time decisions without escalation delays.
- Scalability & Global Readiness
As trials advance, demand shifts rapidly—from small Phase I runs through multi‑country Phase III supply. CMOs are better positioned to:
- Secure critical components during shortages
- Stock standardized materials in advance
- Absorb demand spikes without disrupting timelines
Integrated networks also enable smoother transition from clinical to commercial manufacturing, reducing supplier change‑over risk.
- Reduced Sponsor Burden & Hidden “Coordination Tax”
Fragmented outsourcing forces sponsors to manage multiple contracts, timelines, and quality interfaces. Internal webinar materials describe this as the “coordination tax”—a hidden drain on time and resources.
A consolidated CMO model reduces:
- Vendor oversight burden
- Cross‑vendor scheduling risk
- Quality and communication gaps
How Sponsors Minimize Risk When Working with a CMO
- Select a Truly Integrated or “Under-One-Roof/umbrella” Partner
Risk is lowest when manufacturing, primary packaging, and secondary packaging are aligned operationally—even if not always physically co‑located. Ideal CMOs:
- Minimize subcontracting
- Maintain built‑in redundancies where outsourcing is unavoidable
- Enable fast internal decision‑making through short communication lines
- Lock Down Quality & Governance Early
Risk mitigation starts before the first batch:
- Robust Quality Agreements defining GMP scope and responsibilities
- Clear deviation, escalation, and change‑control processes
- Agreed audit cadence and inspection readiness expectations
Sponsors consistently favor CMOs that demonstrate proactive quality management rather than reactive compliance.
- Build Flexibility into Packaging Strategy
Using pre‑qualified packaging components and standardized configurations reduces both supply and execution risk. Solutions like Priority Pack or equivalent rapid‑response models:
- Eliminate long material lead times
- Enable immediate packaging upon drug availability
- Support fast cohort starts and resupply needs
- Pressure‑Test Transition & Change Management
Sponsors should evaluate how a CMO handles:
- Tech transfer
- Mid‑study changes
- Site or scale transitions
RFP evaluation criteria repeatedly emphasize demonstrated transition capability and adaptability under uncertainty, not just technical fit.
- Prioritize Communication & Transparency
Finally, risk is minimized when CMOs operate as an extension of the sponsor’s team:
- Proactive issue flagging
- Clear KPI visibility
Regular operational and quality touchpoints
Benefit from a discussion between industry veterans who will address:
- The benefits of using an ‘under one roof’ Umbrella partner for your trial
- How a fragmented outsourcing approach can increase risks
- How you can build flexibility into your packaging strategy to reduce supply risk
Back
